Angelalign TechnologyFRA:77D 69 Net Margin % is 6.60% as of Dec. 2025, which is 42% below its 10-year median of 11.45. GuruFocus rates FRA:77D with a GF Score™ of 69/100 and a GF Value™ of €11.62 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Angelalign Technology ranks better than 66.75% on this metric.
The historical rank and industry rank for Angelalign Technology's Net Margin % or its related term are showing as below:
FRA:77D'
s Net Margin % Range Over the Past 10 Years
Min: 3.59 Med: 11.45 Max: 22.48
Current: 7.69
FRA:77D's Net Margin % is ranked better than 66.75% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs FRA:77D: 7.69
Angelalign Technology (FRA:77D) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Angelalign Technology Net Margin % Related Terms
Angelalign Technology Net Margin % Historical Data
* Premium members only.
The historical data trend for Angelalign Technology's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:77D vs ISRG, BDX, MDLN: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, Angelalign Technology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Angelalign Technology Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Angelalign Technology's Net Margin % distribution charts can be found below:
* The bar in red indicates where Angelalign Technology's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Angelalign Technology (FRA:77D) has a Net Margin % of 6.60% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Angelalign Technology and its competitors. This is 42% below median its historical median of 11.45. Over the past decade, Angelalign Technology's Net Margin % has ranged from 3.59 to 22.48. According to the industry distribution chart, Angelalign Technology ranks #271 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 33.3%.
Is Angelalign Technology's Net Margin % too high?
Angelalign Technology's current Net Margin % of 6.60% is 42% below median its 10-year median of 11.45. Over the past 10 years, this metric has ranged from a low of 3.59 to a high of 22.48. The Medical Devices & Instruments industry median Net Margin % is 2.07. Angelalign Technology's value of 6.60% is 218.8% above this industry median. Based on the distribution chart, Angelalign Technology ranks #271 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Angelalign Technology has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Angelalign Technology's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Angelalign Technology ranks #271 out of 815 companies for Net Margin %. This puts Angelalign Technology in the upper half of its industry. The industry median Net Margin % is 2.07. Angelalign Technology's value of 6.60% is 218.8% above this benchmark. Historically, Angelalign Technology's own Net Margin % has ranged from 3.59 to 22.48 over the past decade. While the company's 10-year median is 11.45 vs. the industry median of 2.07, Angelalign Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Angelalign Technology's current Net Margin % of 6.60% is 218.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Angelalign Technology and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Angelalign Technology's current Net Margin % is 6.60%, which is 42% below median its own 10-year median of 11.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angelalign Technology stock overvalued right now?
Based on GuruFocus' analysis, Angelalign Technology (FRA:77D) is currently considered Significantly Undervalued. The stock's GF Value™ is €11.62, compared to a current price of €8.15 — trading 29.9% below its estimated fair value. The current Net Margin % is 6.60%, which is 42% below median its 10-year median of 11.45 and 218.8% above the Medical Devices & Instruments industry median of 2.07. Angelalign Technology's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Angelalign Technology (FRA:77D), the current Net Margin % is 6.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Angelalign Technology (FRA:77D) Overvalued in 2026?
Based on GuruFocus' analysis, Angelalign Technology stock appears to be undervalued.
The current stock price of €8.15 is trading 29.9% below its estimated GF Value™ of €11.62.
GuruFocus considers Angelalign Technology to be Significantly Undervalued.
Key valuation signals for FRA:77D:
Net Margin %: 6.60% (42% below median its 10-year median of 11.45)
GF Value™: €11.62 vs. price of €8.15 (29.9% below fair value)
Industry Position: 218.8% above the Medical Devices & Instruments median (#271 of 815)
No single metric tells the full story. See the FRA:77D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Angelalign Technology Inc is an investment holding company. It is principally engaged in clear aligner treatment solutions, including treatment planning services, manufacturing, and marketing of clear aligners. The company provides dental professionals with self-developed digital orthodontic solutions. The company's Angelalign clear aligner system facilitates dental professionals throughout the entire clear aligner treatment process, including digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, and helps dental professionals design, review, and modify treatment plans.
69GF Score
Get the complete analysis for FRA:77D
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:77D has been successfully added to your 
